Health Catalyst (NASDAQ:HCAT) Given New $10.00 Price Target at Wells Fargo & Company

Health Catalyst (NASDAQ:HCAT) had its price objective reduced by Wells Fargo & Company from $13.00 to $10.00 in a report released on Tuesday,Benzinga reports. They currently have an overweight rating on the stock.

A number of other brokerages also recently issued reports on HCAT. Canaccord Genuity Group lowered their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of Health Catalyst in a report on Friday, October 4th. Piper Sandler reissued an “overweight” rating and set a $12.00 price objective (up from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Royal Bank of Canada dropped their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Finally, Citigroup decreased their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a research note on Friday, January 10th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $10.91.

Health Catalyst Price Performance

HCAT opened at $5.79 on Tuesday. Health Catalyst has a 1 year low of $5.35 and a 1 year high of $10.99. The stock has a 50-day moving average price of $7.39 and a 200-day moving average price of $7.51. The firm has a market cap of $352.32 million, a PE ratio of -4.29 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last issued its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The firm had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. During the same quarter in the prior year, the company posted ($0.22) EPS. The company’s quarterly revenue was up 3.5% on a year-over-year basis. Sell-side analysts predict that Health Catalyst will post -0.33 earnings per share for the current fiscal year.

Insider Activity at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $8.94, for a total transaction of $67,050.00. Following the completion of the transaction, the insider now directly owns 236,950 shares in the company, valued at approximately $2,118,333. The trade was a 3.07 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jason Alger sold 19,599 shares of the stock in a transaction that occurred on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $163,063.68. Following the completion of the sale, the chief financial officer now directly owns 86,712 shares of the company’s stock, valued at $721,443.84. This represents a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,169 shares of company stock worth $639,174. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Dynamic Advisor Solutions LLC purchased a new position in shares of Health Catalyst in the fourth quarter valued at about $180,000. Inspire Investing LLC lifted its holdings in Health Catalyst by 14.2% in the 4th quarter. Inspire Investing LLC now owns 56,379 shares of the company’s stock worth $399,000 after purchasing an additional 7,019 shares in the last quarter. SG Americas Securities LLC boosted its stake in Health Catalyst by 21.7% in the 4th quarter. SG Americas Securities LLC now owns 27,382 shares of the company’s stock worth $194,000 after purchasing an additional 4,874 shares during the period. Avanza Fonder AB purchased a new stake in Health Catalyst during the 4th quarter valued at approximately $184,000. Finally, Franklin Resources Inc. grew its holdings in Health Catalyst by 5.8% during the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock valued at $857,000 after buying an additional 5,687 shares in the last quarter. Institutional investors own 85.00% of the company’s stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.